| Literature DB >> 15265063 |
W Sterry1, J Barker, W-H Boehncke, J D Bos, S Chimenti, E Christophers, M De La Brassinne, C Ferrandiz, C Griffiths, A Katsambas, K Kragballe, C Lynde, A Menter, J-P Ortonne, K Papp, J Prinz, B Rzany, J Ronnevig, J-H Saurat, M Stahle, F M Stengel, P Van De Kerkhof, J Voorhees.
Abstract
Psoriasis is a chronic, immune-mediated disorder that usually requires long-term treatment for control. Approximately 25% of patients have moderate to severe disease and require phototherapy, systemic therapy or both. Despite the availability of numerous therapeutic options, the long-term management of psoriasis can be complicated by treatment-related limitations. With advances in molecular research and technology, several biological therapies are in various stages of development and approval for psoriasis. Biological therapies are designed to modulate key steps in the pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles. The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of biological therapies into clinical practice are discussed.Entities:
Mesh：
Year: 2004 PMID： 15265063 DOI： 10.1111/j.1365-2133.2004.06070.x
Source DB: PubMed Journal: Br J Dermatol ISSN： 0007-0963 Impact factor: 9.302